216 related articles for article (PubMed ID: 35752865)
1. Safety, efficacy and biomarkers analysis of mesenchymal stromal cells therapy in ARDS: a systematic review and meta-analysis based on phase I and II RCTs.
Wang J; Luo F; Suo Y; Zheng Y; Chen K; You D; Liu Y
Stem Cell Res Ther; 2022 Jun; 13(1):275. PubMed ID: 35752865
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials.
Wang F; Li Y; Wang B; Li J; Peng Z
Crit Care; 2023 Jan; 27(1):31. PubMed ID: 36670442
[TBL] [Abstract][Full Text] [Related]
3. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
4. Immunonutrition for acute respiratory distress syndrome (ARDS) in adults.
Dushianthan A; Cusack R; Burgess VA; Grocott MP; Calder PC
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012041. PubMed ID: 30677127
[TBL] [Abstract][Full Text] [Related]
5. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.
Monsel A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Nguekap Tchoumba O; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Malard-Castagnet S; Burrel S; Rosenzwajg M; Tchitchek N; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Ropers J; Menasché P; Larghero J;
Crit Care; 2022 Feb; 26(1):48. PubMed ID: 35189925
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.
Lu W; Yan L; Tang X; Wang X; Du J; Zou Z; Li L; Ye J; Zhou L
J Transl Med; 2024 Jun; 22(1):550. PubMed ID: 38851730
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19.
Taufiq H; Shaik Fakiruddin K; Muzaffar U; Lim MN; Rusli S; Kamaluddin NR; Esa E; Abdullah S
Ther Adv Respir Dis; 2023; 17():17534666231158276. PubMed ID: 37128999
[TBL] [Abstract][Full Text] [Related]
8. The safety profile of mesenchymal stem cell therapy administered through intrathecal injections for treating neurological disorders: a systematic review and meta-analysis of randomised controlled trials.
Mesa Bedoya LE; Camacho Barbosa JC; López Quiceno L; Barrios Arroyave F; Halpert K; España Peña JA; Salazar Uribe JC
Stem Cell Res Ther; 2024 May; 15(1):146. PubMed ID: 38764070
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Mesenchymal Stem Cell Therapy in Patients with Acute Myocardial Infarction: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Yu J; Zhang RF; Mao YL; Zhang H
Curr Stem Cell Res Ther; 2022; 17(8):793-807. PubMed ID: 34397334
[TBL] [Abstract][Full Text] [Related]
11. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review and Meta-Analysis: Safety and Efficacy of Mesenchymal Stem Cells Therapy for Heart Failure.
Shen T; Xia L; Dong W; Wang J; Su F; Niu S; Wang Q; Fang Y
Curr Stem Cell Res Ther; 2021; 16(3):354-365. PubMed ID: 32867655
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.
Zheng G; Huang L; Tong H; Shu Q; Hu Y; Ge M; Deng K; Zhang L; Zou B; Cheng B; Xu J
Respir Res; 2014 Apr; 15(1):39. PubMed ID: 24708472
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.
Wilson JG; Liu KD; Zhuo H; Caballero L; McMillan M; Fang X; Cosgrove K; Vojnik R; Calfee CS; Lee JW; Rogers AJ; Levitt J; Wiener-Kronish J; Bajwa EK; Leavitt A; McKenna D; Thompson BT; Matthay MA
Lancet Respir Med; 2015 Jan; 3(1):24-32. PubMed ID: 25529339
[TBL] [Abstract][Full Text] [Related]
15. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
Matthay MA; Calfee CS; Zhuo H; Thompson BT; Wilson JG; Levitt JE; Rogers AJ; Gotts JE; Wiener-Kronish JP; Bajwa EK; Donahoe MP; McVerry BJ; Ortiz LA; Exline M; Christman JW; Abbott J; Delucchi KL; Caballero L; McMillan M; McKenna DH; Liu KD
Lancet Respir Med; 2019 Feb; 7(2):154-162. PubMed ID: 30455077
[TBL] [Abstract][Full Text] [Related]
16. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal Stromal Cells Attenuate Infection-Induced Acute Respiratory Distress Syndrome in Animal Experiments: A Meta-Analysis.
Fengyun W; LiXin Z; Xinhua Q; Bin F
Cell Transplant; 2020; 29():963689720969186. PubMed ID: 33164559
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review.
Sadeghi B; Ringdén O; Gustafsson B; Castegren M
Front Immunol; 2022; 13():963445. PubMed ID: 36426365
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological agents for adults with acute respiratory distress syndrome.
Lewis SR; Pritchard MW; Thomas CM; Smith AF
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD004477. PubMed ID: 31334568
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stromal cells as a therapeutic intervention for COVID-19: a living systematic review and meta-analysis protocol.
Kirkham AM; Monaghan M; Bailey AJM; Shorr R; Lalu MM; Fergusson DA; Allan DS
Syst Rev; 2021 Sep; 10(1):249. PubMed ID: 34526123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
